Aug 28, 2019

ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--Aug. 28, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston, MA.

In addition, Dr. Marc Schegerin will participate in the hosted panel discussion: Focusing the Laser on Precision Oncology, at 3:00 PM. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.

About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; miransertib (ARQ 092), a potent and selective inhibitor of the AKT serine/threonine kinase, in a planned registrational trial with cohorts in Proteus syndrome and PROS to initiate in 2019; ARQ 751, a next generation highly potent and selective AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA in collaboration with Basilea and Sinovant. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.

Source: ArQule, Inc.

Corporate Contact:
Kathleen Farren
Investor Relations &
Executive Assistant to the CFO
ir@arqule.com

Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations (646) 751-4366
cait@lifescipublicrelations.com

www.ArQule.com

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.